Gerresheimer AG

• 14.07.2020 – 07:00

  Gerresheimer with strong second quarter

  Duesseldorf (ots) - - Implementation of growth strategy beginning to deliver results - Group revenues increase to EUR 363m with 4.6% organic growth in core business - 6.9% organic growth in adjusted EBITDA to EUR 84m - Impacts of pandemic under control; potential vaccination campaigns open opportunities for specialty glass vials - Revenue guidance for 2020 ...

  Ein Dokument

  mehr

• 24.06.2020 – 15:21

  Annual General Meeting of Gerresheimer AG approves dividend increase to EUR 1.20 per share

  Duesseldorf (ots) - Payment of a dividend of EUR 1.20 per share was approved at the virtual Annual General Meeting of Gerresheimer AG. "In 2019, we paved the way for profitable growth and achieved a substantial improvement in the Company's culture and dynamic. We are investing and working to grow our ...

  Ein Dokument

  mehr

• 16.06.2020 – 14:00

  Leading pharma packaging companies commit to supply for Covid-19 fight

  Düsseldorf (ots) - Stevanato Group, SCHOTT, and Gerresheimer confirm the readiness to support future Covid-19 Vaccine with pharmaceutical containers The CEOs of Gerresheimer, Stevanato Group, and SCHOTT are committed to ensuring ample supply of pharmaceutical containers for any Covid-19 vaccine and ...

  Ein Dokument

  mehr

• 09.04.2020 – 07:00

  Gerresheimer business model robust

  Duesseldorf (ots) - - Stable business model as key supplier to pharma and healthcare industry - Gerresheimer sustains growth path. Revenue guidance for 2020 in the mid single-digit percentage range and adjusted EBITDA margin of around 21% confirmed - Refinancing of EUR 190m promissory loan maturing in November 2020 secured ahead of time - First quarter level with prior year, as expected: revenues EUR 304m, ...

  Ein Dokument

  mehr

• 19.02.2020 – 07:30

  Gerresheimer sets foundation for profitable growth in 2019

  Duesseldorf (ots) - -Foundation for sustainable and profitable growth laid in 2019: Annual revenue growth in the mid-single-digit percentage range targeted for 2020 and subsequent years -2019 operating targets met: Underlying revenues reach EUR 1.40bn and underlying adjusted EBITDA EUR 293m -Further increase in proposed dividend to EUR 1.20 per share from ...

  Ein Dokument

  mehr

• 10.10.2019 – 08:33

  Gerresheimer advances growth and technology projects in third quarter

  Düsseldorf (ots) - - Revenues up 1.4 % on the prior-year quarter to EUR 358.6m - Adjusted EBITDA at EUR 72.2m in third quarter of 2019 - Adjusted net income at EUR 30.7m in third quarter of 2019 - New innovation center for pharmaceutical glass opened in the US - Successful refinancing by a EUR 550.0m ...

  Ein Dokument

  mehr

• 07.10.2019 – 12:15

  Gerresheimer opens Glass Innovation and Technology Center in the U.S.

  Düsseldorf/Vineland, New Jersey (ots) - Gerresheimer is driving innovation in pharmaceutical glass, primary packaging glass products, technologies and digitized processes. In the future, highly qualified engineers at the recently opened "Gx Glass Innovation and Technology Center" will develop innovative ...

  Ein Dokument

  mehr

• 11.07.2019 – 07:30

  Gerresheimer reports strong second quarter

  Duesseldorf (ots) - - Revenues up 7.2% on the prior-year quarter to EUR 356.5m - Adjusted EBITDA at EUR 74.2m in second quarter of 2019 (Q2 2018: EUR 71.1m), excluding EUR 26.2m from derecognition of contingent purchase price components in connection with Sensile Medical acquisition - Revenue guidance confirmed without change; guidance on adjusted EBITDA at ...

  Ein Dokument

  mehr

• 14.05.2019 – 10:00

  Dr. Bernd Metzner to become Chief Financial Officer of Gerresheimer AG on May 15, 2019

  Düsseldorf (ots) - Dr. Bernd Metzner (48) takes up the position of Chief Financial Officer of Gerresheimer AG on May 15, 2019. Dr. Metzner had been Chief Financial Officer of SDAX-listed Ströer SE & Co. KGaA since 2014. "I very much welcome the financial expertise and years of industry experience that ...

  Ein Dokument

  mehr

• 11.04.2019 – 07:30

  Gerresheimer makes good start into the new financial year

  Duesseldorf (ots) - - Revenues up 6.3% on the prior-year quarter to EUR 308.5m - Adjusted EBITDA at EUR 145.9m in first quarter of 2019 (Q1 2018: EUR 52.6m), comprising of EUR 53.6m plus EUR 92.3m from partial derecognition of contingent purchase price components connected to the Sensile Medical acquisition - Guidance for adjusted EBITDA at constant ...

  Ein Dokument

  mehr

• 07.03.2019 – 13:00

  Gerresheimer is investing in a new plant in Skopje, North Macedonia, for medical plastic systems and syringes

  Duesseldorf/Skopje (North Macedonia) (ots) - Gerresheimer AG is to build a new plant in Skopje, Republic of North Macedonia. "As part of our growth strategy, we require additional manufacturing capacity and are expanding our European production ...

  Ein Dokument

  mehr

• 14.02.2019 – 07:30

  Gerresheimer back on growth path and sets course for the future

  Duesseldorf (ots) - - Revenues at constant exchange rates up 4.3% in the financial year 2018 to EUR 1,406.7m - Adjusted EBITDA at constant exchange rates at EUR 307.5m, excluding the Advanced Technologies Division and other one-off effects, and despite substantially negative energy costs and resin prices - Strong adjusted net income after non-controlling ...

  Ein Dokument

  mehr

• 28.11.2018 – 10:00

  Dr. Bernd Metzner to become Chief Financial Officer of Gerresheimer AG

  Düsseldorf (ots) - Dr. Bernd Metzner (48) is to become Chief Financial Officer of Gerresheimer AG, taking up office at the latest on July 1, 2019. Dr. Bernd Metzner has been Chief Financial Officer of SDAX-listed Ströer SE & Co. KGaA since 2014. "In Dr. Bernd Metzner, we have gained a highly ...

  Ein Dokument

  mehr

• 11.10.2018 – 07:56

  Gerresheimer increases revenues by 8.8% and successfully integrates Sensile Medical

  Düsseldorf (ots) - - Revenues at constant exchange rates up 8.8% in third quarter of 2018 to EUR 364.4m - Adjusted EBITDA at constant exchange rates - excluding Sensile Medical and negative effects relating to the exemption from electricity network charges - increased by EUR 1.3m in third quarter to EUR ...

  Ein Dokument

  mehr

• 11.10.2018 – 07:46

  Andreas Schütte steps down from Management Board of Gerresheimer AG

  Düsseldorf (ots) - Andreas Schütte (56) will step down from the Management Board of Gerresheimer AG at his own request as of February 28, 2019 in order to pursue new career challenges. The Supervisory Board of Gerresheimer AG approved this wish at its meeting yesterday. Andreas Schütte has served on ...

  Ein Dokument

  mehr

• 27.09.2018 – 11:00

  Micro pump for Parkinson's treatment from Gerresheimer subsidiary Sensile Medical receives European CE declaration of conformity

  Duesseldorf/Olten (ots) - A wearable micro pump from Sensile Medical has received EU certification for the European market. A European pharma company has obtained a CE declaration of conformity for the pump, which is specially designed for the ...

  Ein Dokument

  mehr

• 06.09.2018 – 12:04

  Dietmar Siemssen appointed new CEO of Gerresheimer AG

  Duesseldorf (ots) - - Dietmar Siemssen to assume as Chief Executive Officer on November 1, 2018 - Previously held position as Stabilus CEO - Speaker of the Management Board and CFO Rainer Beaujean will not extend contract after April 30, 2019 Dietmar Siemssen (55) will join the Management Board of Gerresheimer AG as Chief Executive Officer on November 1, ...

  Ein Dokument

  mehr

• 11.07.2018 – 21:37

  Gerresheimer extends business model and increases growth forecast

  Düsseldorf (ots) - - With the acquisition of Sensile Medical, Gerresheimer is extending its business model in the direction of an Original Equipment Manufacturer (OEM) for drug delivery platforms with digital and electronic capabilities for pharmaceutical and biopharmaceutical customers. The purchase ...

  Ein Dokument

  mehr

• 12.04.2018 – 07:30

  Gerresheimer raises earnings per share in first quarter due to US tax reform

  Düsseldorf (ots) - - Revenues at constant exchange rates EUR 299.2m in first quarter of 2018, as expected, stable relative to prior-year period; organic revenue growth 0.4% - Adjusted EBITDA at constant exchange rates EUR 54.9m, as budgeted below the EUR 59.0m prior-year figure - Development of US ...

  Ein Dokument

  mehr

• 22.02.2018 – 07:30

  

  4

  Gerresheimer reports strong fourth quarter after difficult first nine months

  Ein Dokument

  mehr

• 05.02.2018 – 20:22

  Dr. Christian Fischer resigns as CEO of Gerresheimer AG

  Düsseldorf (ots) - Dr. Christian Fischer, Chairman of the Management Board of Gerresheimer AG, will leave the Company with immediate effect. Dr. Fischer has asked for an amicable premature termination of his services due to personal reasons. Such decision is not based on diverging views regarding the strategy or business performance of the Company. The ...

  Ein Dokument

  mehr

• 23.01.2018 – 20:57

  Gerresheimer expects significant positive effects from the US tax reform in 2018

  Düsseldorf (ots) - On December 22, 2017, the US President signed the US tax reform, also known as the Tax Cuts and Jobs Act. The main changes from Gerresheimer's standpoint concern the reduction of the federal corporate tax rate from previously 35 % to now 21 % effective from January 1, 2018 and the ...

  Ein Dokument

  mehr

• 08.01.2018 – 10:00

  

  Dr. Lukas Burkhardt new member of the Management Board at Gerresheimer AG

  Ein Dokument

  mehr

• 11.10.2017 – 07:30

  Gerresheimer in Q3 2017: Slight improvement in adjusted EBITDA margin

  Düsseldorf (ots) - - Revenues down from EUR 350.4m in Q3 2016 to EUR 331.5m in Q3 2017; organic decrease of 4.3%. Adjusted EBITDA margin slightly improved to 23.4% (Q3 2016: 23.2%) - EBITDA leverage, at 2.6, back at same level as of November 30, 2016 and thus significantly better than expected - ...

  Ein Dokument

  mehr

• 31.08.2017 – 10:00

  

  Dr. Christian Fischer to succeed Uwe Röhrhoff as CEO of Gerresheimer AG

  Ein Dokument

  mehr

• 13.07.2017 – 07:30

  Gerresheimer expecting recovery in second half year

  Düsseldorf (ots) - - Revenues in second quarter of 2017 down 2.2% to EUR 339.5m as expected - Adjusted EBITDA margin 22.3%, versus 23.2% in prior-year quarter - Slight increase in Adjusted EBITDA leverage to 2.7 due to dividend payout and bond interest - More specific guidance for the financial year 2017 After a moderate second quarter, Gerresheimer AG ...

  Ein Dokument

  mehr

• 06.04.2017 – 07:30

  Gerresheimer confirms guidance despite moderate start to the year

  Duesseldorf (ots) - - Revenues down 5.4% in first quarter of 2017 to EUR 302.8m - Adjusted EBITDA margin at 19.8%, as in prior year - EBITDA leverage unchanged at 2.6 - Guidance for financial year 2017 confirmed, with consolidated revenues initially at lower end of range Gerresheimer AG made a moderate start to financial year 2017, as expected. With ...

  Ein Dokument

  mehr

• 15.02.2017 – 07:30

  Gerresheimer delivers sustained profitability growth in 2016 and proposes a dividend increase of 23.5%

  Düsseldorf (ots) - - Proposed dividend of EUR 1.05 per share (2015: EUR 0.85 per share) marks an increase of 23.5% - Revenues up 7.2% in financial year 2016 to EUR 1,375.5m - Revenues at constant exchange rates EUR 1,383.1m with 2.9% organic revenue ...

  Ein Dokument

  mehr

• 12.09.2016 – 08:00

  Gerresheimer to sell Life Science Research business

  Düsseldorf (ots) - - Gerresheimer and Chase Scientific Glass, Inc. are to sell their joint venture (51/49%) Kimble Chase to Duran Group, a portfolio company of One Equity Partners - Total transaction enterprise value of USD 131m for 100% of the business In line with its strategy of focusing on packaging and device solutions for pharmaceutical customers, ...

  Ein Dokument

  mehr

• 07.07.2016 – 07:30

  Gerresheimer substantially increases earnings in second quarter

  Duesseldorf (ots) - - Revenues up 4.0% to EUR 370.5m - Adjusted EBITDA rises 17.5% to EUR 84.7m - Adjusted EBITDA margin climbs to 22.8% - Adjusted earnings per share surpass prior-year quarter by 34.5% to reach EUR 1.13 Gerresheimer AG, one of the leading partners to the pharma and healthcare industry ...

  Ein Dokument

  mehr